Those suffering from asthma and chronic obstructive pulmonary disease (COPD) attacks are set to be given a 'game-changing' new treatment that could save more lives.
According to medical researchers, it's the first real leap in the treatment for those with COPD and asthma.
More than five million Brits live with asthma, with a further 1.2 million being diagnosed with COPD. Both conditions kill, with roughly three people losing their lives every day from an asthma attack.
Advert
Now, a new study has found that an injection is a more effective way to treat the conditions instead of prescribing steroid tablets. Such a change would also cut the need for further treatment by 30 percent, according to a study.
Benralizumab: what is it and how will it treat asthma?
Benralizumab is a monoclonal antibody that targets specific white blood cells, called eosinophils, to reduce lung inflammation. It is currently used as a repeat treatment for severe asthma at a low dose, but a new clinical trial has found that a higher single dose can be very effective if injected at the time of a flare-up.
The findings, published in the Lancet Respiratory Medicine, included 158 people who needed medical attention in A&E for their asthma or COPD attack (COPD is a group of lung conditions that cause breathing difficulties).
Patients were given a quick blood test to see what type of attack they were having, with those suffering an 'eosinophilic exacerbation' involving eosinophils (a type of white blood cell) being suitable for treatment.
Around 50 percent of asthma attacks are eosinophilic exacerbations, as are 30 percent of COPD ones, according to the scientists. The clinical trial, led by King’s College London and carried out at Oxford University Hospitals NHS Foundation Trust and Guy’s and St Thomas’ NHS Foundation Trust, saw patients randomly split into three groups.
One group received the benralizumab injection and dummy tablets, another received standard care (prednisolone steroids 30mg daily for five days) and a dummy injection, and the third group received both the benralizumab injection and steroids.
The benefits of Benralizumab
After 28 days, respiratory symptoms of cough, wheeze, breathlessness and sputum were found to be better in people on benralizumab.
And after 90 days, there were four times fewer people in the benralizumab group who failed treatment compared with those receiving steroids. Treatment with the benralizumab injection also took longer to fail, meaning fewer visits to a GP or hospital for patients, researchers said.
Furthermore, people also reported a better quality of life on the new regime. Scientists at King’s said steroids can have severe side-effects such as increasing the risk of diabetes and osteoporosis, meaning switching to benralizumab could provide huge benefits.
What are the scientists saying?
Lead investigator Professor Mona Bafadhel, from King’s, said: “This could be a game-changer for people with asthma and COPD. Treatment for asthma and COPD exacerbations have not changed in 50 years, despite causing 3.8 million deaths worldwide a year combined.
“Benralizumab is a safe and effective drug already used to manage severe asthma. We’ve used the drug in a different way – at the point of an exacerbation – to show that it’s more effective than steroid tablets, which is the only treatment currently available.”
Researchers said benralizumab could also potentially be administered safely at home or in a GP practice, as well as in A&E.
First author Dr Sanjay Ramakrishnan, clinical senior lecturer at the University of Western Australia, said: “Our study shows massive promise for asthma and COPD treatment.
“COPD is the third leading cause of death worldwide but treatment for the condition is stuck in the 20th century. We need to provide these patients with life-saving options before their time runs out.”
Dr Samantha Walker, director of research and innovation at Asthma and Lung UK, welcomed the findings but said: “It’s appalling that this is the first new treatment for those suffering from asthma and COPD attacks in 50 years, indicating how desperately underfunded lung health research is.”
AstraZeneca provided the drug for the study and funded the research, but had no input into trial design, delivery, analysis or interpretation.
Tom Earnshaw